Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Atom
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:can_be_used_to |
treatment of p53 mutant cancers
|
| gptkbp:casnumber |
643202-88-0
|
| gptkbp:chemical_formula |
C16 H15 N3 O3 S
|
| gptkbp:clinical_trial |
Phase I
|
| gptkbp:discovered_by |
gptkb:Boehringer_Ingelheim
|
| https://www.w3.org/2000/01/rdf-schema#label |
nutlin-3a
|
| gptkbp:invention |
gptkb:Boehringer_Ingelheim
|
| gptkbp:mechanism_of_action |
inhibits MDM2-p53 interaction
|
| gptkbp:related_to |
p53 tumor suppressor protein
|
| gptkbp:targets |
gptkb:MDM2
|
| gptkbp:used_in |
cancer therapy
|
| gptkbp:bfsParent |
gptkb:nutlin-3
|
| gptkbp:bfsLayer |
6
|